🧬 SinoBioData Academic Portal
Open AccessDOI: 10.12307/2026.21520Original Research

10-Hydroxy-2-decenoic acid facilitates osteogenic differentiation via the enhancement of autophagy and antioxidant capacity

HU Jie¹,HE Hui¹,MA Fengyu¹,SHEN Xiaotian¹,YUAN Zhangqin¹,LIANG Ting¹,HAN Fengxuan¹

Department of Orthopedic Surgery, First Affiliated Hospital, Soochow University; Orthopedic Institute, Soochow Medical College, Soochow University

Read Executive PreviewQuick FAQ
10-Hydroxy-2-decenoic acid facilitates osteogenic differentiation via the enhancement of autophagy and antioxidant capacity
Graphical Abstract / Figure
Published In
Chinese Journal of Tissue Engineering Research
Published:January 15, 2026Edition:Vol 1906, Issue 34 • pp. 100-112Citation:HU Jie et al. (2026), Chinese Journal of Tissue Engineering Research
Impact FactorPremier Chinese Biomedical Journal indexed in SinoBioData: Chinese Journal of Tissue Engineering Research (中国组织工程研究).
Sponsored Research Partner

Key Takeaways & Executive Findings

  • • 10-HDA promotes proliferation and osteogenic differentiation of rat bone marrow mesenchymal stem cells (BMSCs) while inhibiting osteoclast formation. • 10-HDA activates the SIRT1/FOXO1 signaling pathway, leading to FOXO1 deacetylation and nuclear translocation, which upregulates autophagy-related proteins and antioxidant enzymes. • Under oxidative stress, 10-HDA enhances the antioxidant capacity of BMSCs and reduces apoptosis and senescence via the SIRT1/FOXO1 pathway. • 10-HDA shows potential as a therapeutic agent for osteoporosis by restoring the balance between bone formation and resorption.
Sponsored Research Highlight

Abstract

BACKGROUND: 10-Hydroxy-2-decenoic acid (10-HDA) exhibits potent anti-inflammatory, antioxidant, and immunomodulatory effects, but its role in regulating bone metabolism remains unclear. OBJECTIVE: To investigate the regulatory effects and potential mechanisms of 10-HDA in bone remodeling. METHODS: Rat bone marrow mesenchymal stem cells (BMSCs) were cultured with different concentrations of 10-HDA (0, 0.5, 1, 2, 4 mmol/L); cytoskeletal staining, live/dead staining, and CCK-8 assay were used to assess cell morphology, viability, and proliferation. For osteogenic differentiation, BMSCs were cultured with 10-HDA (0, 0.5, 1, 2 mmol/L) and osteogenic induction; alkaline phosphatase (ALP) and alizarin red staining were performed, and osteogenic-related protein expression was analyzed by western blot and immunofluorescence. Mouse bone marrow mononuclear cells were induced to differentiate into macrophages and cultured in osteoclast differentiation medium with different concentrations of 10-HDA (0, 0.5, 1, 2 mmol/L); tartrate-resistant acid phosphatase (TRAP) and F-actin staining were used to detect osteoclast formation. BMSCs were serum-starved for 6 h and then cultured normally, divided into control, 10-HDA, 10-HDA+AS1842856 (FOXO1 inhibitor), and 10-HDA+EX-527 (SIRT1 inhibitor) groups; 10-HDA concentration was 0.5 mmol/L. Western blot and immunofluorescence were used to analyze SIRT1/FOXO1 pathway activation and expression of autophagy- and osteogenesis-related proteins. BMSCs were divided into control, H2O2, and H2O2+10-HDA groups; 10-HDA concentration was 0.5 mmol/L; after H2O2 treatment for 24 h, corresponding drug interventions were applied; after osteogenic induction, ALP and alizarin red staining were performed. BMSCs were divided into five groups: control, H2O2, H2O2+10-HDA, H2O2+10-HDA+AS1842856, and H2O2+10-HDA+EX-527; 10-HDA concentration was 0.5 mmol/L; after H2O2 treatment for 24 h, corresponding drug interventions were applied; western blot was used to detect SIRT1/FOXO1 signaling pathway and antioxidant-related protein expression; TUNEL and β-galactosidase staining were used to assess apoptosis and senescence. RESULTS AND CONCLUSION: Cytoskeletal staining, live/dead staining, and CCK-8 assay showed that 0.5, 1, 2 mmol/L 10-HDA promoted proliferation of rat BMSCs; these three concentrations were selected for subsequent experiments. ALP, alizarin red staining, western blot, and immunofluorescence analysis showed that 0.5 mmol/L 10-HDA promoted osteogenic differentiation and mineralization of rat BMSCs and increased osteogenic-related protein expression. TRAP and F-actin staining showed that 0.5 mmol/L 10-HDA significantly inhibited osteoclast formation. Western blot and immunofluorescence showed that 10-HDA activated the SIRT1/FOXO1 signaling pathway, promoted FOXO1 deacetylation and nuclear translocation, and upregulated autophagy-related proteins and antioxidant enzymes. ALP and alizarin red staining showed that under oxidative stress, 10-HDA promoted osteogenic differentiation and mineralization of rat BMSCs. Western blot showed that under oxidative stress, 10-HDA enhanced the antioxidant capacity of rat BMSCs by activating the SIRT1/FOXO1 signaling pathway. TUNEL and β-galactosidase staining showed that under oxidative stress, 10-HDA reduced apoptosis and senescence of rat BMSCs via activation of the SIRT1/FOXO1 signaling pathway. These findings indicate that 10-HDA enhances autophagy and antioxidant capacity through regulation of the SIRT1/FOXO1 signaling pathway, thereby promoting osteogenic differentiation.

1. Introduction

Osteoporosis is a common chronic metabolic bone disease characterized by decreased bone density, destruction of bone microarchitecture, and increased bone fragility, leading to an elevated risk of fractures. Globally, approximately 200 million women and 50 million men suffer from osteoporosis, with over 1.5 million fractures occurring annually due to this condition. Nearly 50% of postmenopausal women face the risk of osteoporosis-related fractures, with 25% experiencing vertebral deformities and 15% suffering hip fractures, severely impacting quality of life and imposing a heavy economic burden.

The pathogenesis of osteoporosis involves multiple factors, including hormonal changes, oxidative stress, chronic inflammation, and dysfunction of bone cells. Among these, the dynamic imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption is considered the core mechanism. Therefore, restoring the balance between bone formation and resorption is of great significance for the effective prevention and treatment of osteoporosis.

SinoBioData Interactive Document Reader
Page 1–5 of Preview
100%
Download Full PDF

Loading authentic research manuscript (Pages 1–5)...

Sponsored Research Partner
Cite This Research Paper
HU Jie, HE Hui, MA Fengyu, SHEN Xiaotian, YUAN Zhangqin, LIANG Ting, HAN Fengxuan (2026). 10-Hydroxy-2-decenoic acid facilitates osteogenic differentiation via the enhancement of autophagy and antioxidant capacity. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21520
SinoBioData Academic & Legal Disclaimer

Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.

Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.

Frequently Asked Questions

What is 10-Hydroxy-2-decenoic acid (10-HDA) and its known biological effects?

10-HDA is an unsaturated fatty acid derived from royal jelly, known for its anti-inflammatory, antioxidant, and immunomodulatory properties. It has potential therapeutic value in diseases such as rheumatoid arthritis, neuroinflammation, tumors, muscle atrophy, and bacterial infections.

How does 10-HDA affect bone marrow mesenchymal stem cells (BMSCs)?

10-HDA promotes the proliferation and osteogenic differentiation of rat BMSCs, as evidenced by increased alkaline phosphatase activity, mineralization, and expression of osteogenic-related proteins. It also inhibits osteoclast formation, suggesting a dual role in bone remodeling.

What is the molecular mechanism underlying 10-HDA's effects on bone metabolism?

10-HDA activates the SIRT1/FOXO1 signaling pathway, leading to FOXO1 deacetylation and nuclear translocation. This upregulates autophagy-related proteins and antioxidant enzymes, enhancing autophagy and antioxidant capacity, which in turn promotes osteogenic differentiation and protects against oxidative stress-induced apoptosis and senescence.

Could 10-HDA be a potential therapeutic agent for osteoporosis?

Yes, by promoting bone formation and inhibiting bone resorption, 10-HDA shows promise as a therapeutic agent for osteoporosis. Its ability to enhance autophagy and antioxidant defense further supports its potential in mitigating oxidative stress-related bone loss.

What experimental models were used in this study?

The study used rat bone marrow mesenchymal stem cells (BMSCs) for osteogenic differentiation assays, mouse bone marrow mononuclear cells for osteoclast differentiation, and oxidative stress models induced by H2O2 to evaluate the protective effects of 10-HDA.

Recommended Scientific Literature & Research Partners

Related Technical Papers & Translations

Research Paper
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.

Read Abstract & PDF
Research Paper
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.

Read Abstract & PDF
Research Paper
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.

Read Abstract & PDF